MX2020010086A - Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas. - Google Patents

Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.

Info

Publication number
MX2020010086A
MX2020010086A MX2020010086A MX2020010086A MX2020010086A MX 2020010086 A MX2020010086 A MX 2020010086A MX 2020010086 A MX2020010086 A MX 2020010086A MX 2020010086 A MX2020010086 A MX 2020010086A MX 2020010086 A MX2020010086 A MX 2020010086A
Authority
MX
Mexico
Prior art keywords
methods
compositions
same
conditions related
hallucinations
Prior art date
Application number
MX2020010086A
Other languages
English (en)
Inventor
Michael Zasloff
Denise Barbut
Original Assignee
Enterin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterin Inc filed Critical Enterin Inc
Publication of MX2020010086A publication Critical patent/MX2020010086A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta solicitud se refiere a métodos para tratar, prevenir y/o desacelerar el inicio o progresión de alucinaciones y/o síntomas relacionados provocados por una variedad de trastornos, con aminoesteroles o sales farmacéuticamente aceptables o derivado de los mismos.
MX2020010086A 2018-03-27 2019-03-25 Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas. MX2020010086A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648661P 2018-03-27 2018-03-27
US201962789437P 2019-01-07 2019-01-07
PCT/US2019/023814 WO2019190950A1 (en) 2018-03-27 2019-03-25 Methods and compositions for treating hallucinations and conditions related to the same

Publications (1)

Publication Number Publication Date
MX2020010086A true MX2020010086A (es) 2021-03-25

Family

ID=68056714

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010086A MX2020010086A (es) 2018-03-27 2019-03-25 Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.

Country Status (9)

Country Link
US (1) US20190298740A1 (es)
EP (1) EP3773600A4 (es)
JP (1) JP2021519349A (es)
KR (1) KR20200146038A (es)
CN (1) CN112312917A (es)
AU (1) AU2019242557A1 (es)
CA (1) CA3094977A1 (es)
MX (1) MX2020010086A (es)
WO (1) WO2019190950A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022035765A1 (en) * 2020-08-10 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Molecular targets for modulation of dissociative and associative states
CN114344288B (zh) * 2022-01-25 2023-07-04 深圳技术大学 盐酸多塞平在制备抗病毒药物中的应用
CN116036239B (zh) * 2023-03-28 2023-06-23 中国人民解放军军事科学院军事医学研究院 Nep1-40在制备特异性抑制幻觉作用的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US20080058300A1 (en) * 2006-04-21 2008-03-06 Mclane Michael Induction of weight loss and the selective inhibition of PTP1B
CA2697744C (en) * 2007-09-06 2016-06-14 Genaera Corporation A method for treating diabetes
US20130245253A1 (en) * 2010-03-26 2013-09-19 Department Of Veterans Affairs Conjugated Neuroactive Steroid Compositions And Methods Of Use
KR101963312B1 (ko) * 2012-04-20 2019-03-28 오에이치알 파마서티컬, 인코포레이티드 Ptp1b 연관 질병의 치료용 아미노스테로이드
US10040817B2 (en) * 2013-10-03 2018-08-07 Enterin Laboratories, Inc. Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
EP3678671A4 (en) * 2017-09-08 2022-12-07 Enterin, Inc. METHODS OF TREATING SLEEP DISORDERS, SLEEP DISTURBANCES AND ASSOCIATED SYMPTOMS USING AMINOSTEROL COMPOSITIONS
MA50536A (fr) * 2017-10-30 2020-09-09 Enterin Inc Nouvelles formes solides de squalamine et procédés pour les produire
US20210260078A1 (en) * 2018-08-03 2021-08-26 Philadelphia Low dosage intranasal aminosterol dosage forms and methods of using the same
WO2020028810A1 (en) * 2018-08-03 2020-02-06 Enterin Laboratories Compositions and methods for treating brain-gut disorders

Also Published As

Publication number Publication date
CA3094977A1 (en) 2019-10-03
EP3773600A4 (en) 2021-12-29
KR20200146038A (ko) 2020-12-31
JP2021519349A (ja) 2021-08-10
US20190298740A1 (en) 2019-10-03
WO2019190950A1 (en) 2019-10-03
EP3773600A1 (en) 2021-02-17
CN112312917A (zh) 2021-02-02
AU2019242557A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2022007432A (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino.
MX2023001876A (es) Derivados de rapamicina.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
SG10201804868PA (en) Compounds for the inhibition of indoleamine-2,3-dioxygenase
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
PH12020551425A1 (en) Rimegepant for cgrp related disorders
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018006223A (es) Moduladores de ror-gamma.
EP4316591A3 (en) Oxysterols and methods of use thereof
MD4812C1 (ro) Derivaţi nucleozidici 4'-substituiţi în calitate de inhibitori ai transcriptazei inverse a HIV
MX371304B (es) Dihidropirrolopiridinas inhibidoras del receptor huérfano-gamma.
WO2015130842A3 (en) Ether compounds for treatment of complement mediated disorders
MX2016010034A (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2020010086A (es) Métodos y composiciones para tratar alucinaciones y afecciones relacionadas con las mismas.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
WO2015168635A3 (en) Compositions and methods for modulating complement factor b expression
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.